Indivior Pharmaceuticals (INDV) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to -$445.0 million.
- Indivior Pharmaceuticals' Enterprise Value fell 3993.71% to -$445.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.0 million, marking a year-over-year decrease of 3993.71%. This contributed to the annual value of -$320.0 million for FY2024, which is 7308.66% up from last year.
- As of Q3 2025, Indivior Pharmaceuticals' Enterprise Value stood at -$445.0 million, which was down 3993.71% from -$510.0 million recorded in Q2 2025.
- In the past 5 years, Indivior Pharmaceuticals' Enterprise Value ranged from a high of -$318.0 million in Q3 2024 and a low of -$1.1 billion during Q4 2021
- Its 5-year average for Enterprise Value is -$675.7 million, with a median of -$731.0 million in 2023.
- In the last 5 years, Indivior Pharmaceuticals' Enterprise Value skyrocketed by 6410.84% in 2024 and then crashed by 3993.71% in 2025.
- Quarter analysis of 5 years shows Indivior Pharmaceuticals' Enterprise Value stood at -$1.1 billion in 2021, then rose by 18.97% to -$893.0 million in 2022, then increased by 18.14% to -$731.0 million in 2023, then surged by 56.22% to -$320.0 million in 2024, then tumbled by 39.06% to -$445.0 million in 2025.
- Its Enterprise Value stands at -$445.0 million for Q3 2025, versus -$510.0 million for Q2 2025 and -$373.0 million for Q1 2025.